
Stimulating insulin secretion from the pancreas when blood glucose rises
Inhibiting glucagon release, which helps prevent excess glucose production by the liver
Slowing gastric emptying, leading to prolonged digestion and steadier blood sugar levels

Available as Victoza (for diabetes) and Saxenda (for weight management)
Available as Ozempic (for diabetes) and Wegovy (for weight management)
Available as Mounjaro (for diabetes and weight management)
GLP-1 agonists help lower blood sugar by increasing insulin secretion and decreasing the amount of glucose produced by the liver. These medications are often added when first line oral drugs such as metformin no longer provide adequate blood sugar control. Clinical studies have also shown that certain GLP-1 agonists can lower the risk of major cardiovascular events in people with type 2 diabetes who already have heart disease.
For people without diabetes, GLP-1 agonists such as Wegovy and Saxenda are FDA approved for weight loss. By boosting feelings of fullness and lowering appetite, these medications help individuals eat less while feeling more satisfied. Studies show that when GLP-1 therapy is paired with healthy lifestyle changes, many patients achieve meaningful and lasting weight loss.
GLP-1 receptor agonists help control blood sugar by boosting insulin release after meals and lowering glucagon levels. This combination prevents sudden spikes in blood glucose and supports steadier day to day glycemic control. Because their action depends on current glucose levels, they carry a much lower risk of causing hypoglycemia than many older diabetes drugs.
A key advantage of GLP-1 therapy is its strong support for long term weight loss and weight maintenance. By slowing the rate at which the stomach empties and sending signals to the brain that enhance feelings of fullness, GLP-1 medications help reduce hunger and make it easier for people to naturally cut back on calorie intake. Clinical research has shown that treatments such as liraglutide, semaglutide, and tirzepatide can produce meaningful and lasting weight loss when they are combined with healthy eating and regular physical activity.



GLP-1/GIP co-agonists stimulate both GLP-1 and GIP receptors at the same time, leading to stronger insulin release and better control of appetite than GLP-1 based therapies alone. By engaging two incretin pathways, these medications provide a more robust way to manage blood sugar and reduce hunger, making them an exciting option for patients with diabetes and obesity.
GLP-1/glucagon co-agonists act on both GLP-1 and glucagon receptors to enhance calorie burning and weight loss while helping to maintain lean muscle mass during treatment.

